Stay updated on Liraglutide Effect on Diastolic Dysfunction in Diabetes Clinical Trial
Sign up to get notified when there's something new on the Liraglutide Effect on Diastolic Dysfunction in Diabetes Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FCmsoUPahhupAzly-cFKcR73xM1Q.uncropped.jpg&w=3840&q=75)
Latest updates to the Liraglutide Effect on Diastolic Dysfunction in Diabetes Clinical Trial page
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has been updated to version v2.10.0, replacing the previous version v2.9.7.SummaryDifference0.4%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value on the web page has changed from 'Show more Show more Revision: v2.9.0' to 'Show less MedlinePlus Genetics related topics: Type 2 diabetes Drug Information available for: Liraglutide FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : Randomized Interventional Model : Parallel Assignment Masking : Triple ( Participant Care Provider Investigator ) Arms and Interventions Participant Group/Arm Intervention/Treatment Active Comparator : Liraglutide arm Patients will be treated with liraglutide (up to 1.8 mg s.c. once daily). Total treatment period will be 18 weeks. Drug : Liraglutide Other Names: Victoza Placebo Comparator : Placebo arm Patients will be treated with placebo (up to equal to 1.8 mg drug dose s.c. once daily). Total treatment period will be 18 weeks. The study will be placebo-controlled with placebo as an add-on to conventional diabetes treatment. Thus, no patient will receive a sub-standard treatment. Drug : Placebo Primary Outcome Measures Outcome Measure Measure Description Time Frame Change in diastolic properties as assessed by CMR. LA passive emptying fraction (%) (before and after glycopyrolate) Measured in week 18 and compared to baseline. Change in diastolic properties as assessed by CMR. LV peak filling rate (ml/s) (before and after glycopyrolate) Measured in week 18 and compared to baseline. Secondary Outcome Measures Outcome Measure Measure Description Time Frame MRI indices of myocardial perfusion Measured in week 18 and compared to baseline. Echocardiographic indices of diastolic dysfunction Measured in week 18 and compared to baseline. Additional Relevant MeSH Terms Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Diabetes Mellitus Diabetes Mellitus, Type 2 Glucagon-Like Peptide-1 Receptor Agonists Hypoglycemic Agents Physiological Effects of Drugs Incretins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Liraglutide Revision: v2.9.1.'SummaryDifference12%
Stay in the know with updates to Liraglutide Effect on Diastolic Dysfunction in Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Liraglutide Effect on Diastolic Dysfunction in Diabetes Clinical Trial page.